GLP-1 therapy has also shown benefit in improving atherothrombosis markers (e.g., inflammation, endothelial dysfunction, clotting in this population
Impaired adipose NAMPT-NAD+-SIRT1-PPAR axis contributes to the development of obesity and its metabolic complications and thus it could be a promising therapeutic target for obesity treatment
International Society for Pharmacoepidemiology
The number of cases involving glucagon-like peptide-1 (GLP-1) drugs, such as Rybelsus, now totals over 2,100 lawsuits
Both drug classes can affect appetite and eating patterns, though through different mechanisms
Tirzepatide targets both the GLP-1 and glucagon receptors, so its a dual agonist